Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Frequently asked questions
What sector does Medicenna Therapeutics Corp (MDNA) operate in?
Medicenna Therapeutics Corp belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Medicenna Therapeutics Corp (MDNA) current stock price?
As of the latest data, Medicenna Therapeutics Corp stock price is CA$0.42, with a previous close of CA$0.43. Medicenna Therapeutics Corp lost -CA$0.01 in the last trading session, representing a -1.18% loss.
What is Medicenna Therapeutics Corp (MDNA) current market capitalization?
Medicenna Therapeutics Corp market cap is approximately 38.77 million.
What is Medicenna Therapeutics Corp (MDNA) Earnings Per Share (EPS)?
The trailing EPS is -CA$0.22, and the forward EPS is -CA$0.36.
What is Medicenna Therapeutics Corp (MDNA) EBITDA?
Medicenna Therapeutics Corp EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -5.43 million.
Does Medicenna Therapeutics Corp (MDNA) pay dividends?
No. Medicenna Therapeutics Corp does not pay a dividend.
When is Medicenna Therapeutics Corp (MDNA) next earnings report?
Medicenna Therapeutics Corp is expected to release its next earnings report on September 30, 2026.
What is Medicenna Therapeutics Corp (MDNA) beta (volatility) score?
Medicenna Therapeutics Corp has a beta of 2.101, indicating very high volatility compared to the market.
